Ruben Mesa, MD, discusses the current challenges in the treatment landscape for researchers treating myelofibrosis (MF) and how a greater understanding of why patients relapse will help investigators overcome these challenges.
In an interview with Targeted Oncology, Tania Jain, MBBS, discussed the role of transplant as treatment of patients with myelofibrosis and the challenges that remain in this space. She also spoke to the treatment options for patients with graft-versus-host-disease.
A report from the Canadian Myeloproliferative Neoplasm Group has outlined different patterns of treatment failure from JAK inhibitor therapy in patients with myelofibrosis. The report, published in JCO Oncology Practice, suggests management practices for each pattern of response.
Ruxolitinib was found to be safe and effective for long-term treatment of patients with polycythemia vera who are resistant to or intolerant of hydroxyurea, according to the 5-year follow-up data from the phase III RESPONSE trial, recently published in The Lancet Haematology.
Ropeginterferon alfa-2b improved responses overtime in patients with polycythemia vera who presented predominantly without splenomegaly compared with hydroxyurea, according to findings from the phase III PROUD-PV clinical trial and its extension study, CONTINUATION-PV.
At the 24th Annual International Congress on Hematologic Malignancies, host by Physicians’ Education Resourceâ, LLC, Ruben Mesa, MD, who is director of the UT San Antonio MD Anderson Cancer Center, presented available and emerging therapy options for patients who require additional MF therapy following ruxolitinib.